DelveInsight’s “Colorectal Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Colorectal Cancer Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Colorectal Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Colorectal Cancer: An Overview
Colorectal Cancer, also known as bowel cancer, colon cancer, or rectal cancer, is any cancer that affects the colon and rectum. Colorectal cancer occurs when tumors form in the lining of the large intestine. It is common in both men and women. The risk of developing colorectal cancer rises after age 50.
Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide, with more than 1.85 million cases and 850 000 deaths annually. Of new colorectal cancer diagnoses, 20% of patients have metastatic disease at presentation, and another 25% who present with the localized disease will later develop metastases.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Colorectal Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Colorectal Cancer market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Colorectal Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Colorectal Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Colorectal Cancer market or expected to get launched during the study period. The analysis covers Colorectal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Colorectal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market
Colorectal Cancer Therapeutics Analysis
In July 2020, the U.S. Food and Drug Administration approved Keytruda (pembrolizumab) for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
There are approx. 150+ key companies which are developing therapies for Colorectal Cancer. Currently, Mirati Therapeutics has its Colorectal Cancer drug candidates in the most advanced stage of clinical development.
Major Players in the Colorectal Cancer Therapeutics Market include:
Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, MacroGenics, Amgen, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Dainippon Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Merck Sharp & Dohme Corp., AstraZeneca, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Pregen ShenZhen Biotechnology, Puma Biotechnology, G1 Therapeutics, Mologen AG, Sumitomo Dainippon Pharma, Celyad Oncology, Nitto BioPharma, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, and many others.
Colorectal Cancer Emerging Drugs Covered in the report include:
• Patritumab Deruxtecan: Daiichi Sankyo Company
• Adagrasib: Mirati Therapeutics
• Etrumadenant: Arcus Biosciences
• AL2846: Advenchen Laboratories
• Onvansertib: Cardiff Oncology
And many more
Further product details are provided in the report. Download the sample report to learn more about the emerging products and key companies in the market:
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Colorectal Cancer Competitive Intelligence Analysis
4. Colorectal Cancer Market Overview at a Glance
5. Colorectal Cancer Disease Background and Overview
6. Colorectal Cancer Patient Journey
7. Colorectal Cancer Epidemiology and Patient Population
8. Colorectal Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Colorectal Cancer Unmet Needs
10. Key Endpoints of Colorectal Cancer Treatment
11. Colorectal Cancer Marketed Products
12. Colorectal Cancer Emerging Therapies
13. Colorectal Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Colorectal Cancer Market Outlook (7 major markets)
16. Colorectal Cancer Access and Reimbursement Overview
17. KOL Views on the Colorectal Cancer Market.
18. Colorectal Cancer Market Drivers
19. Colorectal Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Nocturnal Enuresis Market
“Nocturnal Enuresis Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Nocturnal Enuresis Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/